Current paradigms in epigenetic anticancer therapeutics and future challenges.

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Genetic and epigenetic alterations are key drivers of tumorigenesis and cancer development.
• Epigenetic modifications, including DNA methylation and histone modifications, play crucial roles in gene transcription.
• Reversing epigenetic alterations in tumors offers a promising avenue for developing effective epigenetic cancer treatments.

Purpose of the Study:

• To review epigenetic alterations in cancer.
• To discuss strategies for utilizing these alterations for therapeutic benefit.
• To highlight challenges and future directions in epigenetic cancer therapy.

Main Methods:

• Review of current literature on epigenetic alterations in cancer.
• Analysis of epigenetic drugs targeting DNA methyltransferase (DNMT) and histone deacetylases (HDACs).
• Discussion of clinical studies involving epigenetic inhibitors like FK228, SAHA, and MS-275.

Main Results:

• Epigenetic drugs targeting DNMT and HDACs are FDA-approved and show promise in clinical studies.
• Despite progress, challenges remain in developing specific, effective inhibitors with minimal side effects.
• Deeper understanding of tumor pathology and epigenetic alterations is needed for optimized therapy.

Conclusions:

• Epigenetic therapy holds significant potential for cancer treatment by reversing aberrant epigenetic modifications.
• Further research is required to overcome challenges related to inhibitor specificity, efficacy, and understanding tumor-specific epigenetic landscapes.
• Developing more targeted and effective epigenetic strategies is crucial for advancing cancer therapy.